|
1
|
Azamjah N, Soltan-Zadeh Y and Zayeri F:
Global trend of breast cancer mortality rate: A 25-year study.
Asian Pac J Cancer Prev. 20:2015–2020. 2019.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2018. CA Cancer J Clin. 68:7–30. 2018.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Sorlie T, Tibshirani R, Parker J, Hastie
T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, et
al: Repeated observation of breast tumor subtypes in independent
gene expression data sets. Proc Natl Acad Sci USA. 100:8418–8423.
2003.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Perou CM: Molecular stratification of
triple-negative breast cancers. Oncologist. 16 (Suppl 1):S61–S70.
2011.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Goldhirsch A, Wood WC, Coates AS, Gelber
RD, Thürlimann B and Senn HJ: Panel members. Strategies for
subtypes-dealing with the diversity of breast cancer: Highlights of
the St. Gallen International Expert Consensus on the Primary
Therapy of Early Breast Cancer 2011. Ann Oncol. 22:1736–1747.
2011.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Goldhirsch A, Winer EP, Coates AS, Gelber
RD, Piccart-Gebhart M, Thürlimann B and Senn HJ: Panel members.
Personalizing the treatment of women with early breast cancer:
Highlights of the St Gallen International Expert Consensus on the
Primary Therapy of Early Breast Cancer 2013. Ann Oncol.
24:2206–2223. 2013.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Rosenberg PS, Barker KA and Anderson WF:
Estrogen receptor status and the future burden of invasive and in
situ breast cancers in the United States. J Natl Cancer Inst.
107(djv159)2015.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Jatoi I, Anderson WF, Jeong JH and Redmond
CK: Breast cancer adjuvant therapy: Time to consider its
time-dependent effects. J Clin Oncol. 29:2301–2304. 2011.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Sweeney C, Bernard PS, Factor RE, Kwan ML,
Habel LA, Quesenberry CP Jr, Shakespear K, Weltzien EK, Stijleman
IJ, Davis CA, et al: Intrinsic subtypes from PAM50 gene expression
assay in a population-based breast cancer cohort: Differences by
age, race, and tumor characteristics. Cancer Epidemiol Biomarkers
Prev. 23:714–724. 2014.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Anderson WF, Rosenberg PS and Katki HA:
Tracking and evaluating molecular tumor markers with cancer
registry data: HER2 and breast cancer. J Natl Cancer Inst.
106(dju093)2014.PubMed/NCBI View Article : Google Scholar
|
|
12
|
El Hachem G, Gombos A and Awada A: Recent
advances in understanding breast cancer and emerging therapies with
a focus on luminal and triple-negative breast cancer. F1000Res 8:
F1000 Faculty Rev-591, 2019.
|
|
13
|
Cardoso F, Senkus E, Costa A, Papadopoulos
E, Aapro M, André F, Harbeck N, Aguilar Lopez B, Barrios CH, Bergh
J, et al: 4th ESO-ESMO international consensus guidelines for
advanced breast cancer (ABC 4)†. Ann Oncol. 29:1634–1657.
2018.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Rasha F, Sharma M and Pruitt K: Mechanisms
of endocrine therapy resistance in breast cancer. Mol Cell
Endocrinol. 532(111322)2021.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Mavratzas A and Marme F: Treatment of
luminal metastatic breast cancer beyond CDK4/6 inhibition: Is there
a standard of care in clinical practice? Breast Care (Basel).
16:115–128. 2021.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Andrysik Z, Bender H, Galbraith MD and
Espinosa JM: Multi-omics analysis reveals contextual tumor
suppressive and oncogenic gene modules within the acute hypoxic
response. Nat Commun. 12(1375)2021.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Rouault JP, Falette N, Guéhenneux F,
Guillot C, Rimokh R, Wang Q, Berthet C, Moyret-Lalle C, Savatier P,
Pain B, et al: Identification of BTG2, an antiproliferative
p53-dependent component of the DNA damage cellular response
pathway. Nat Genet. 14:482–486. 1996.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Rouault JP, Prevot D, Berthet C, Birot AM,
Billaud M, Magaud JP and Corbo L: Interaction of BTG1 and
p53-regulated BTG2 gene products with mCaf1, the murine homolog of
a component of the yeast CCR4 transcriptional regulatory complex. J
Biol Chem. 273:22563–22569. 1998.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Stoica GE, Franke TF, Moroni M, Mueller S,
Morgan E, Iann MC, Winder AD, Reiter R, Wellstein A, Martin MB and
Stoica A: Effect of estradiol on estrogen receptor-alpha gene
expression and activity can be modulated by the ErbB2/PI 3-K/Akt
pathway. Oncogene. 22:7998–8011. 2003.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Mao B, Zhang Z and Wang G: BTG2: A rising
star of tumor suppressors (review). Int J Oncol. 46:459–464.
2015.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Zhang L, Huang H, Wu K, Wang M and Wu B:
Impact of BTG2 expression on proliferation and invasion of gastric
cancer cells in vitro. Mol Biol Rep. 37:2579–2586.
2010.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Coppola V, Musumeci M, Patrizii M,
Cannistraci A, Addario A, Maugeri-Saccà M, Biffoni M,
Francescangeli F, Cordenonsi M, Piccolo S, et al: BTG2 loss and
miR-21 upregulation contribute to prostate cell transformation by
inducing luminal markers expression and epithelial-mesenchymal
transition. Oncogene. 32:1843–1853. 2013.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Chu TY, Yang JT, Huang TH and Liu HW:
Crosstalk with cancer-associated fibroblasts increases the growth
and radiation survival of cervical cancer cells. Radiat Res.
181:540–547. 2014.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Shang D, Xie C, Hu J, Tan J, Yuan Y, Liu Z
and Yang Z: Pancreatic cancer cell-derived exosomal microRNA-27a
promotes angiogenesis of human microvascular endothelial cells in
pancreatic cancer via BTG2. J Cell Mol Med. 24:588–604.
2020.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Chen Z, Chen X, Lu B, Gu Y, Chen Q, Lei T,
Nie F, Gu J, Huang J, Wei C, et al: Up-regulated LINC01234 promotes
non-small-cell lung cancer cell metastasis by activating VAV3 and
repressing BTG2 expression. J Hematol Oncol. 13(7)2020.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Xu Z, Wang Y, Xiong J, Cui F, Wang L and
Peng H: NUSAP1 knockdown inhibits cell growth and metastasis of
non-small-cell lung cancer through regulating BTG2/PI3K/Akt
signaling. J Cell Physiol. 235:3886–3893. 2020.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Devanand P, Kim SI, Choi YW, Sheen SS, Yim
H, Ryu MS, Kim SJ, Kim WJ and Lim IK: Inhibition of bladder cancer
invasion by Sp1-mediated BTG2 expression via inhibition of DNA
methyltransferase 1. FEBS J. 281:5581–5601. 2014.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Kawakubo H, Brachtel E, Hayashida T, Yeo
G, Kish J, Muzikansky A, Walden PD and Maheswaran S: Loss of B-cell
translocation gene-2 in estrogen receptor-positive breast carcinoma
is associated with tumor grade and overexpression of cyclin d1
protein. Cancer Res. 66:7075–7082. 2006.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Takahashi M, Hayashida T, Okazaki H, Miyao
K, Jinno H and Kitagawa Y: Loss of B-cell translocation gene 2
expression in estrogen receptor-positive breast cancer predicts
tamoxifen resistance. Cancer Sci. 105:675–682. 2014.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Hamadneh L, Abu-Irmaileh B, Al-Majawleh M,
Bustanji Y, Jarrar Y and Al-Qirim T: Doxorubicin-paclitaxel
sequential treatment: Insights of DNA methylation and gene
expression changes of luminal A and triple negative breast cancer
cell lines. Mol Cell Biochem. 476:3647–3654. 2021.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Huang Q, Zahid KR, Chen J, Pang X, Zhong
M, Huang H, Pan W, Yin J, Raza U, Zeng J, et al: KIN17 promotes
tumor metastasis by activating EMT signaling in luminal-A breast
cancer. Thorac Cancer. 12:2013–2023. 2021.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Barrett T and Edgar R: Mining microarray
data at NCBI's gene expression omnibus (GEO)*. Methods
Mol Biol. 338:175–190. 2006.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Edgar R, Domrachev M and Lash AE: Gene
Expression omnibus: NCBI gene expression and hybridization array
data repository. Nucleic Acids Res. 30:207–210. 2002.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Graham K, de las Morenas A, Tripathi A,
King C, Kavanah M, Mendez J, Stone M, Slama J, Miller M, Antoine G,
et al: Gene expression in histologically normal epithelium from
breast cancer patients and from cancer-free prophylactic mastectomy
patients shares a similar profile. Br J Cancer. 102:1284–1293.
2010.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Huang da W, Sherman BT and Lempicki RA:
Systematic and integrative analysis of large gene lists using DAVID
bioinformatics resources. Nat Protoc. 4:44–57. 2009.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Anaya J: OncoLnc: Linking TCGA survival
data to mRNAs, miRNAs, and lncRNAs. PeerJ Computer Sci.
2(e67)2016.
|
|
37
|
Rhodes DR, Kalyana-Sundaram S, Mahavisno
V, Varambally R, Yu J, Briggs BB, Barrette TR, Anstet MJ,
Kincead-Beal C, Kulkarni P, et al: Oncomine 3.0: Genes, pathways,
and networks in a collection of 18,000 cancer gene expression
profiles. Neoplasia. 9:166–180. 2007.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Chandrashekar DS, Bashel B, Balasubramanya
SAH, Creighton CJ, Ponce-Rodriguez I, Chakravarthi BVSK and
Varambally S: UALCAN: A portal for facilitating tumor subgroup gene
expression and survival analyses. Neoplasia. 19:649–658.
2017.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408.
2001.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Perou CM, Sørlie T, Eisen MB, van de Rijn
M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA,
et al: Molecular portraits of human breast tumours. Nature.
406:747–752. 2000.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Sorlie T, Perou CM, Tibshirani R, Aas T,
Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey
SS, et al: Gene expression patterns of breast carcinomas
distinguish tumor subclasses with clinical implications. Proc Natl
Acad Sci USA. 98:10869–10874. 2001.PubMed/NCBI View Article : Google Scholar
|
|
42
|
van de Vijver MJ, He YD, van't Veer LJ,
Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C,
Marton MJ, et al: A gene-expression signature as a predictor of
survival in breast cancer. New Engl J Med. 347:1999–2009.
2002.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Paik S, Shak S, Tang G, Kim C, Baker J,
Cronin M, Baehner FL, Walker MG, Watson D, Park T, et al: A
multigene assay to predict recurrence of tamoxifen-treated,
node-negative breast cancer. New Engl J Med. 351:2817–2826.
2004.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Ettl J: Luminal metastatic breast cancer:
Current concepts and future approaches. Breast Care (Basel).
16:99–100. 2021.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Gonzalez-Conde M, Yanez-Gomez C,
Lopez-Lopez R and Costa C: Liquid biopsy: A new tool for overcoming
CDKi resistance mechanisms in luminal metastatic breast cancer. J
Pers Med. 11(407)2021.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Luftner D, Hartkopf AD, Lux MP, Overkamp
F, Tesch H, Titzmann A, Pöschke P, Wallwiener M, Müller V, Beckmann
MW, et al: Challenges and Opportunities for Real-world evidence in
metastatic luminal breast cancer. Breast Care (Basel). 16:108–114.
2021.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Melamed J, Kernizan S and Walden PD:
Expression of B-cell translocation gene 2 protein in normal human
tissues. Tissue Cell. 34:28–32. 2002.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Wei S, Hao C, Li X, Zhao H, Chen J and
Zhou Q: Effects of BTG2 on proliferation inhibition and
anti-invasion in human lung cancer cells. Tumour Biol.
33:1223–1230. 2012.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Wagener N, Bulkescher J, Macher-Goeppinger
S, Karapanagiotou-Schenkel I, Hatiboglu G, Abdel-Rahim M,
Abol-Enein H, Ghoneim MA, Bastian PJ, Müller SC, et al: Endogenous
BTG2 expression stimulates migration of bladder cancer cells and
correlates with poor clinical prognosis for bladder cancer
patients. Br J Cancer. 108:973–982. 2013.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Zhang YJ, Wei L, Liu M, Li J, Zheng YQ,
Gao Y and Li XR: BTG2 inhibits the proliferation, invasion, and
apoptosis of MDA-MB-231 triple-negative breast cancer cells. Tumour
Biol. 34:1605–1613. 2013.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Jinghua H, Qinghua Z, Chenchen C, Lili C,
Xiao X, Yunfei W, Zhengzhe A, Changxiu L and Hui H: MicroRNA
miR-92a-3p regulates breast cancer cell proliferation and
metastasis via regulating B-cell translocation gene 2 (BTG2).
Bioengineered. 12:2033–2044. 2021.PubMed/NCBI View Article : Google Scholar
|
